MedTrace Logo

Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease

NCT05107271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 252

Last updated 2025-06-08

No results posted yet for this study

Summary

The project is essential to understand the impact of the COVID-19 pandemic in patients with Chronic Liver Disease (CLD).

The impact has been felt due to direct risk of COVID infection in self, or in caregivers, lack of access to services during lockdown, interruptions in transplant listing and waitlist mortality. Briefly, the following points will be focused during the study.

1. Long haul COVID-19 related symptoms.
2. Impact on health and delay in interventions or drug therapy due to interruption of physical outpatient services.
3. Impact on emergency admissions due to refractory ascites, new decompensation, variceal bleeding etc
4. Impact on delayed transplant listing and waitlist mortality
5. Impact on post-transplant patients with lack of access to drug monitoring/ physical OPD
6. Impact on delay in interventions due to hepatobiliary malignancy.
7. Effects of COVID-19 infection, vaccination (single dose, two doses) and no vaccination and protective antibody levels in patients with chronic liver disease and post-transplant recipients.
8. Determination of dose protocol and need for booster vaccination in patients with CLD and post liver transplant recipients.

Conditions

  • COVID-19
  • Chronic Liver Failure
  • Cirrhosis, Liver
  • Portal Hypertension
  • Liver Transplant Disorder

Interventions

DIAGNOSTIC_TEST

COVID-19 serosurvey

COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity

Sponsors & Collaborators

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Principal Investigators

  • Virendra Singh, MD DM · Post Graduate Institute of Medical Education and Research, Chandigarh

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2022-12-15
Completion
2024-03-15

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05107271 on ClinicalTrials.gov